Wixela Inhub Powder
Product Images NDC 0378-9320

35 FDA label images from Mylan Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Wixela Inhub (NDC 0378-9320). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Instructions For Use Figure A (Image 01)

Instructions For Use Figure A (Image 01)
An instructional diagram of the Wixela Inhub inhalation device for fluticasone propionate and salmeterol powder. It highlights device features including the dosage label, dose counter, and grip areas on the inhaler for respiratory use. The label shows the dose strength with a counter displaying the remaining doses.*
FDA Label Image

Fluticasone Propionate Structural Formula (Image 02)

Fluticasone Propionate Structural Formula (Image 02)
Chemical structure of fluticasone propionate, one of the active ingredients in Wixela Inhub (fluticasone propionate and salmeterol). The diagram shows the molecular arrangement of atoms and bonds in the compound.*
FDA Label Image

Salmeterol Zinofoate Structural Formula (Image 03)

Salmeterol Zinofoate Structural Formula (Image 03)
Chemical structure of fluticasone propionate and salmeterol, the active ingredients in Wixela Inhub inhalation powder. The image depicts molecular diagrams for both compounds showing their chemical bonds and functional groups.*
FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 04)

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 04)
A line graph showing percentage change in FEV1 over 12 weeks comparing fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg, fluticasone propionate 100 mcg, salmeterol 50 mcg, and placebo. The graph includes a legend with symbols for each treatment and sample sizes at various weeks.*
FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 05)

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 05)
A line graph titled 'First Treatment Day' showing percent change in FEV1 over 12 hours on the x-axis. It compares the effects of fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. Each treatment group's data points are plotted over time, illustrating changes in lung function performance throughout the day.*
FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 06)

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 06)
A line graph titled 'Last Treatment Day (Week 12)' illustrating percent change in FEV1 relative to Day 1 baseline over 12 hours. The graph compares fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. Lines show changes over time in lung function for four groups, measured by different symbols.*
FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Image 07)

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Image 07)
A line graph depicting percent change in FEV1 over 24 weeks for three groups: fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The x-axis represents weeks, and the y-axis shows percent change in FEV1. Sample sizes (N) for each group at various time points are listed below the graph.*
FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Image 08)

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Image 08)
A line graph showing the percent change in FEV1 over 24 weeks for three groups: fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg twice daily, fluticasone propionate 250 mcg twice daily, and placebo. The graph includes baseline FEV1 values for each group and plots data points from Day 1 through week 24, showing the combined treatment group with the highest improvement, followed by fluticasone alone, and then placebo. Sample sizes at various time points are listed below the graph.*
FDA Label Image

Instructions For Use Figure B (Image 09)

Instructions For Use Figure B (Image 09)
An instructional diagram of the Wixela Inhub inhaler showing labeled parts including the mouthpiece cover, mouthpiece, air vents, and yellow lever. The illustration also depicts a person using the inhaler by placing the mouthpiece near their mouth to inhale the medication.*
FDA Label Image

Instructions For Use Figure C (Image 10)

Instructions For Use Figure C (Image 10)
Instructional illustration titled Figure C showing a hand holding the Wixela Inhub inhaler device. The thumb is pushing down a lever on the side to prepare the inhaler for use, with an inset close-up highlighting the dose counter at the top of the device.*
FDA Label Image

Instructions For Use Figure D (Image 11)

Instructions For Use Figure D (Image 11)
An instructional illustration depicting a hand holding the Wixela Inhub inhalation device. The image emphasizes the proper grip and operation, including a detailed close-up of the device's mouthpiece to guide respiratory inhalation technique.*
FDA Label Image

Instructions For Use Figure F (Image 12)

Instructions For Use Figure F (Image 12)
Instructional illustrations showing how to use the Wixela Inhub inhalation powder device. Figure E depicts a person exhaling away from the mouthpiece, while Figure F shows the person inhaling the powder medication deeply after activating the device.*
FDA Label Image

Instructions For Use Figure G (Image 13)

Instructions For Use Figure G (Image 13)
Illustration showing a hand holding the Wixela Inhub inhalation device with an inset detail highlighting the device's dose counter displaying the number 59, indicating remaining doses. The diagram includes an inset of a person using the inhaler by inhaling through the mouthpiece.*
FDA Label Image

Instructions For Use Dose Counter Figure 1 (Image 14)

Instructions For Use Dose Counter Figure 1 (Image 14)
Illustration showing a person exhaling into the sink, presumably to demonstrate proper inhaler use or cleaning instructions for Wixela Inhub powder inhalation product.*
FDA Label Image

Instructions For Use Dose Counter Figure 2 (Image 15)

Instructions For Use Dose Counter Figure 2 (Image 15)
An instructional diagram illustrating the counter display on the Wixela Inhub inhaler, showing 60 doses remaining. The image highlights the dose counter window on the side of the inhaler device.*
FDA Label Image

Instructions For Use Dose Counter Figure 3 (Image 16)

Instructions For Use Dose Counter Figure 3 (Image 16)
An instructional diagram illustrating the dosage indicator on the Wixela Inhub inhaler. The indicator shows '9 doses left' on a numbered scale, guiding users on the remaining doses in the device.*
FDA Label Image

Instructions For Use Figure E (Image 17)

Instructions For Use Figure E (Image 17)
Wixela Inhub inhalation powder label showing the proprietary name and the dose counter at 0 doses left, indicating an empty inhaler. The label includes the generic names fluticasone propionate and salmeterol. The product is a respiratory inhalation powder by Mylan Pharmaceuticals Inc.*
FDA Label Image

Instructions For Use Figure H (Image 18)

Instructions For Use Figure H (Image 18)
An instructional diagram showing a hand holding the Wixela Inhub inhaler. The image illustrates pressing down the mouthpiece with a thumb to activate the device, with an inset highlighting the mouthpiece and showing airflow direction indicated by a blue arrow pointing downward.*
FDA Label Image

Wixela 100/50 Carton Label Step 3a (Image 19)

Wixela 100/50 Carton Label Step 3a (Image 19)
An instructional illustration showing a hand holding the Wixela Inhub inhaler device, demonstrating how to press the yellow button to prepare a dose for inhalation. The close-up inset highlights the yellow button on the device.*
FDA Label Image

Wixela 100/50 Carton Label Step 2 (Image 20)

Wixela 100/50 Carton Label Step 2 (Image 20)
An instructional diagram showing a person inhaling medication from a Wixela Inhub inhaler device. The image depicts the correct oral inhalation technique, highlighting how the patient should place the mouth on the device to inhale the powder medication.*
FDA Label Image

Wixela 100/50 Carton Label Step 3b (Image 21)

Wixela 100/50 Carton Label Step 3b (Image 21)
An instructional illustration showing a person using Wixela Inhub inhaler. The person holds the inhaler device close to their mouth, demonstrating the proper respiratory inhalation technique for the powder medication. The image highlights the inhaler design and user interaction.*
FDA Label Image

Wixela 100/50 Carton Label Step 1 (Image 22)

Wixela 100/50 Carton Label Step 1 (Image 22)
Instructional diagram showing a user holding a Wixela Inhub inhaler for respiratory powder drug delivery. It illustrates the steps to prepare the device for inhalation by rotating the base and indicates a dose counter on the device showing the remaining doses.*
FDA Label Image

Wixela 100/50 Carton Label Step 4 (Image 23)

Wixela 100/50 Carton Label Step 4 (Image 23)
Box packaging label for Wixela Inhub 100/50 fluticasone propionate and salmeterol inhalation powder, USP. It contains one Inhub inhalation device with 60 doses of powder for oral inhalation. Labeler is Mylan Pharmaceuticals Inc. The label includes dosage strength, usage reminders, storage instructions, a barcode, and illustrated step-by-step inhaler use instructions.*
FDA Label Image

Wixela 250/50 Carton Label Step 3a (Image 24)

Wixela 250/50 Carton Label Step 3a (Image 24)
An instructional diagram showing a person holding a Wixela Inhub inhaler device with one hand while using the other hand to press down on the lever or button, suggesting the action to load or activate the dose for respiratory inhalation.*
FDA Label Image

Wixela Inhalation Powder 100/50 Carton Label (Image 25)

Wixela Inhalation Powder 100/50 Carton Label (Image 25)
An instructional illustration showing a person holding the Wixela Inhub inhaler device with a close-up inset of the mouthpiece and inhaler mechanism, demonstrating how to properly hold and use the respiratory powder inhaler for fluticasone propionate and salmeterol.*
FDA Label Image

Wixela 250/50 Carton Label Step 3b (Image 26)

Wixela 250/50 Carton Label Step 3b (Image 26)
An instructional illustration showing a person inhaling from an inhaler device labelled Wixela Inhub, a respiratory powder inhaler containing fluticasone propionate and salmeterol. The image demonstrates the proper inhalation technique for using the device.*
FDA Label Image

Wixela 250/50 Carton Label Step 1 (Image 27)

Wixela 250/50 Carton Label Step 1 (Image 27)
Illustration showing a person using the Wixela Inhub inhaler by inhaling powder medication through the mouthpiece. The device is held in one hand, demonstrating correct inhalation technique for respiratory administration.*
FDA Label Image

Wixela 250/50 Carton Label Step 2 (Image 28)

Wixela 250/50 Carton Label Step 2 (Image 28)
An instructional illustration showing hands holding and operating a Wixela Inhub inhaler device. The image emphasizes the steps to open the inhaler, indicated by blue arrows, and includes a magnified inset detailing the inhaler's top part for clearer understanding.*
FDA Label Image

Wixela Inhalation Powder 250/50 Carton Label (Image 29)

Wixela Inhalation Powder 250/50 Carton Label (Image 29)
Packaging label for Wixela Inhub 250/50 powder for oral inhalation. The label indicates the product contains fluticasone propionate and salmeterol as inhalation powders, USP. It specifies a dose strength of 250 mcg of fluticasone propionate and 50 mcg of salmeterol per inhalation. The package contains one Inhub inhalation device with 60 doses. Labeler is Mylan Pharmaceuticals Inc. Instructions for use and storage information are included on the sides.*
FDA Label Image

Wixela 250/50 Carton Label Step 4 (Image 30)

Wixela 250/50 Carton Label Step 4 (Image 30)
An instructional illustration showing a hand holding a Wixela Inhub inhaler device from the front. The image includes an arrow pointing downward, indicating a step in the inhalation or device use process. A small inset at the top right corner shows a zoomed-in view of a part of the inhaler device, likely highlighting its functional component or mouthpiece.*
FDA Label Image

Wixela 500/50 Carton Label Step 3a (Image 31)

Wixela 500/50 Carton Label Step 3a (Image 31)
An instructional illustration showing a person holding a Wixela Inhub inhaler device. The image focuses on the proper grip and use of the inhaler for respiratory powder delivery, with a zoomed inset highlighting a key component of the inhaler mechanism.*
FDA Label Image

Wixela 500/50 Carton Label Step 1 (Image 32)

Wixela 500/50 Carton Label Step 1 (Image 32)
An instructional illustration showing a person exhaling or preparing to use a respiratory inhalation device, depicted as a powder inhaler labeled in detail at the bottom. The diagram highlights the inhalation process for using the inhaler device.*
FDA Label Image

Wixela 500/50 Carton Label Step 2 (Image 33)

Wixela 500/50 Carton Label Step 2 (Image 33)
An instructional diagram showing how to use the Wixela Inhub inhaler. It depicts a person holding the inhaler device close to their mouth, appearing ready to inhale the powder medication through the mouthpiece.*
FDA Label Image

Wixela 500/50 Carton Label Step 3b (Image 34)

Wixela 500/50 Carton Label Step 3b (Image 34)
Illustration showing the use of Wixela Inhub powder inhaler. It depicts a person holding the inhaler with a finger pressing down on the lever to activate it. A close-up highlights the dose counter displaying the number 59, and a blue arrow indicates the direction to press the lever for dose release.*
FDA Label Image

Wixela 500/50 Carton Label Step 4 (Image 35)

Wixela 500/50 Carton Label Step 4 (Image 35)
Wixela Inhub 500/50 inhalation powder carton for respiratory use contains fluticasone propionate 500 mcg and salmeterol 50 mcg per dose. The label shows a dry powder inhaler with 60 doses per device, manufactured by Mylan Pharmaceuticals Inc. It includes dosage details, storage instructions, and step-by-step usage instructions with illustrations.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.